It's been discussed in previous discussions. For example, the average success rate at Phase 1 less than 10% but above 60% at Phase 3 (much higher due to confirmed safety and confirmed efficacy, albeit in a small, non- statistically significant sample).
The Advanz deal adds confidence re due diligence of Phase 2a and other matters.
If success was 100% likely, the SP would be above $1 now. Current price is an attractive risk-reward situation.
Dimerix (ASX: DXB) Discussion Thread, page-198
-
- There are more pages in this discussion • 443 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
-0.060(9.84%) |
Mkt cap ! $302.3M | |||
| Open | High | Low | Value | Volume |
| 60.5¢ | 61.0¢ | 55.0¢ | $2.309M | 4.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 137019 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.5¢ | 22500 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |